Market insights

Home » Market insights

Uptick in M&A Activity and Investor Cash Expected to Reinvigorate Pharma and Biotech in 2018

The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong. According to EP Vantage, the editorial arm of Evaluate Ltd, the current business friendly stance at the FDA is unlikely [...]

Pharma Integrates: Technological Developments and a New Patient-Payer Value Chain

Reporting on the Pharma Integrates plenary session, A New Value Proposition for Pharma, Melanie Lee, Chief Scientific Officer, BTG, noted that "an issue that came through during our session that products can get all the way through the regulatory pathway and gain, for example FDA approval, yet not be a commercial success." "More examples are seen each [...]

Innovent Biologics Leads Pharma Tech Transfers for 2017

The number of tech transfer deals in the pharmaceutical industry has been increasing for the last 10 years, with the exception of 2012, although the sum of the deal values year-on-year has fluctuated, according to GlobalData, a leading data and analytics company. The most valuable tech transfer deal in 2017 was the $457 million licensing agreement between [...]

Improvements Needed for Suboptimal Clinical Trial Design in Pancreatic Cancer

Progress in pancreatic adenocarcinoma trials is sluggish, which is often attributed to low clinical trial recruitment and substandard design. This results in an inadequate understanding of this notoriously difficult-to-treat disease and poor outcomes for patients, according to GlobalData, a leading data and analytics company. Clinical trial accrual is poor in pancreatic cancer and there is a [...]

Pharma Integrates 2017: Data, Pricing and the Future of CDMOs

Can new commercial models change the innovation investment model? “The patient should be at the centre of everything we do; but, in reality, it’s budgets!” So began the pricing debate at Pharma Integrates 2017. Will precision medicine require a shift to precision payment? Does the unpredictability of the current commercial model threaten investment in these [...]

Pharma Integrates 2017: A New Value Proposition for Pharma

Further insights from the podium as the Pharma Integrates panellists tackle changing product and technological developments and a new patient-payer value chain, and ponder whether the future of pharma is in the hands of drug manufacturing companies In recent years, successful science has improved R&D productivity and new technologies have turned life-threatening conditions into manageable chronic diseases. [...]

Data-Driven Personas Help Take the Edge Off Risked-Based Life Science Contracts

Few recent trends have had as profound an effect on life sciences organisations as the healthcare industry’s transition to value-based care with its focus on outcomes. No longer is it enough to deliver drugs and devices that have proven to be effective in clinical trials. Today, life sciences organisations are being asked to assume part [...]

Singapore’s Pharmaceutical Market Value to Reach $1.15 Billion by 2021

Singapore’s pharmaceutical market is expected to expand from $903 million in 2016 to $1.15 billion by 2021, according to GlobalData, a leading data and analytics company. The company’s latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore, reveals that Singapore’s healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research [...]

CPhI Global Pharma Index: India’s Reputation Improving and Ranks as Third Most Competitive Nation

 CPhI & P-MEC India – organised by UBM – is set to welcome more than 50,000 attendees as the CPhI Global Pharma Index shows the country’s efforts to improve its reputation are paying dividends. India emerged successful in a number of key areas and was ranked by international pharma companies as the third most competitive nation globally. The [...]

Crohn’s Disease: Diagnosed Incident Cases Set to Increase

The burden of diagnosed Crohn’s disease (CD) is expected to grow between 2016 and 2026 in the seven major markets (7MM) . Epidemiologists from GlobalData, a leading data and analysis company, forecast an increase in the number of diagnosed incident cases, most notably in the US and Japan. The chart presents the expected changes in [...]